The long-term safety and potential chronic toxicity of glyconanoparticles are one of the key challenges in achieving clinical transformation. At CD BioGlyco, we provide the glyconanoparticle chronic toxicity study service, which aims to comprehensively evaluate the long-term toxicity of glyconanoparticles and provide a scientific basis for the safety and effectiveness of the product.
Our service relies on the advanced GlycoNano™ Platform, which integrates a series of core technologies such as the synthesis, characterization, functionalization, and biological evaluation of glyconanoparticles. On this basis, we further expanded Glyconanoparticle Preclinical Study Service, covering multiple dimensions of research such as acute toxicity, subchronic toxicity, genotoxicity, and reproductive toxicity to comprehensively evaluate the safety of glyconanoparticles. Glyconanoparticle Safety Pharmacology Service focuses on the evaluation of drug safety pharmacology to ensure that glyconanoparticles will not have adverse effects on the physiological functions of the human body while exerting their therapeutic effects.
Our glyconanoparticle chronic toxicity study service employs rigorous scientific methodologies to assess the chronic toxicity of glyconanoparticles, which are vital components in nanomedicine due to their unique properties and applications. We understand that each client may have specific requirements based on their research goals. Our platform is flexible, allowing for customization in terms of nanoparticle modifications, detection methodologies, and specific endpoints of interest. We recommend consulting with our scientific team to tailor the study design, ensuring alignment with research objectives.
Our research begins with the precise synthesis of glyconanoparticles. We utilize advanced glycochemistry and nanotechnology to customize glyconanoparticles with specific physicochemical properties and biological activities. The size, morphology, surface charge, and functional modifications of these particles are all carefully designed to meet diverse research needs. Following synthesis, we employ techniques such as high-resolution transmission electron microscopy (TEM), dynamic light scattering (DLS), Fourier transform infrared spectroscopy (FTIR), and X-ray diffraction (XRD) to comprehensively characterize the structure, size distribution, and surface properties of the glyconanoparticles.
Appropriate dosing regimens are selected based on preliminary studies, ensuring that the exposure levels simulate realistic scenarios of human exposure. By administering different doses at various time points, we simulate the long-term exposure of glyconanoparticles in humans, assessing their long-term effects on organisms.
Utilizing isotopic labeling, fluorescence imaging, and mass spectrometry analysis, we track the biodistribution, accumulation, metabolism, and excretion pathways of glyconanoparticles within organisms, revealing their biological behavior. Implemented using animal models, particularly rodents, these studies track the distribution, accumulation, and excretion of glyconanoparticles over time. Inductively coupled plasma mass spectrometry (ICP-MS) is often employed to quantitatively measure the presence of nanoparticles in critical organs, providing data on potential bioaccumulation and long-term effects.
Through histological sectioning, immunohistochemical staining, gene expression profiling, and proteomics research, we evaluate the impact of glyconanoparticles on major organs and tissues, including potential cellular damage, inflammatory responses, and genotoxicity. Our toxicologists conduct detailed tissue examinations to identify any nanoparticle-induced changes at the cellular level. This involves staining techniques and imaging technologies that reveal structural alterations in tissues, providing insights into chronic inflammation, fibrosis, or other pathological changes.
We detect blood biochemistry indicators, such as liver and kidney function markers, electrolyte balance, and inflammatory response markers. At the same time, the impact of glyconanoparticles on the Immune System, including cellular and humoral immune responses, is assessed.
The workflow of our glyconanoparticle chronic toxicity study service begins with the structuring of a detailed study design, customized to suit the research objectives. Following this, we conduct pilot studies to fine-tune exposure protocols. Full studies are then carried out, encompassing chronic exposure of selected animal models to glyconanoparticles. Data from these experiments are meticulously analyzed using advanced bioanalytical and histopathological techniques. The service culminates in a comprehensive report that interprets the findings to offer actionable insights for further nanoparticle development and approval processes.
Technology: Study on the chronic toxicity of zinc oxide (ZnO) nanoparticles (NPs)
Published: 2014
Journal: Particle and fibre toxicology
IF: 7.12
Results: The article investigates the chronic toxicity of ZnO NPs through murine inhalation models. Mice were exposed to ZnO NPs for both sub-acute (2 weeks) and sub-chronic (13 weeks) durations to analyze potential pulmonary toxicity. Minimal pulmonary inflammation was observed, with elevated macrophage activity but no severe cytotoxic effects or substantial changes in pulmonary mechanics compared to the control group. ZnO NPs showed low chronic toxicity in the lungs, suggesting limited long-term health risks via inhalation.
Fig.1 Qualitative histopathological evaluation and micrographs of lung tissues of mice exposed to ZnO NPs. (Adamcakova-Dodd, et al., 2014)
At CD BioGlyco, our glyconanoparticle chronic toxicity study service provides robust, reliable, and comprehensive toxicity profiles, aiding in the safe development and use of glyconanoparticles in pharmaceutical and other nanotechnology applications. We sincerely invite you to contact us to explore more possibilities and ensure the success of your glyconanoparticle development project.
Reference
